4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
AstraZeneca (NYSE: AZN) began the week with an eye-popping deal for a potential new cancer drug in a relatively early stage of development. The big pharma will hand its favorite collaboration partner, Daiichi Sankyo (OTC: DSNKY), a whopping $1 billion upfront to develop and commercialize DS-1062, an experimental treatment for lung and breast cancer currently in phase 1 trials.
In addition to a gigantic up-front payment, AstraZeneca could pay its Japanese collaboration partner up to $5 billion in milestone payments. AstraZeneca had lots of reasons to make a confident bet on a program that had been flying under the radar. Here are four of the big ones investors should understand.
Image source: Getty Images.
Source Fool.com
